Pedro Pires Goulart Guimaraes;Cynthia Fernades Ferreira Santos;Robson Augusto Souza Dos Santos;Ivana Silva Lula;Frederico Barros De Sousa;Angelo Márcio Leite Denadai;Rubén Dario Sinisterra Millán
发明人:
Rubén Dario Sinisterra Millán,Cynthia Fernades Ferreira Santos,Robson Augusto Souza Dos Santos,Ivana Silva Lula,Frederico Barros De Sousa,Pedro Pires Goulart Guimaraes,Angelo Márcio Leite Denadai
申请号：
US12513107
公开号：
US08653031B2
申请日:
2006.10.30
申请国别(地区):
US
年份:
2014
代理人:
摘要：
We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus. They may also be used in the study and therapy of cardiovascular, renal, reproductive, dermatological, neoplastic, blood and cerebral diseases, and when formulated in controlled release systems, encapsulated or not in cyclodextrins, for use in stent, with a view to modulate the growth of the neointima after catheterization procedures.
